



HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Sapropterin Dihydrochloride Powder for Oral Solution safely and effectively. See full prescribing information for Sapropterin Dihydrochloride Powder for Oral Solution.

SAPROPTERIN DIHYDROCHLORIDE powder for oral solution

Initial U.S. Approval: 2007

RECENT MAJOR CHANGES	
Warnings and Precautions	12/2019
Upper Gastrointestinal Mucosal Inflammation (5.2)	

INDICATIONS AND USAGE
Sapropterin dihydrochloride powder for oral solution is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. (1)

DOSAGE AND ADMINISTRATION
All patients with PKU who are being treated with sapropterin dihydrochloride powder for oral solution should also be treated with a Phe-restricted diet, including dietary protein and Phe restriction. (2.1)
Starting Dosage
• **Pediatric patients 1 month to 6 years:** The recommended starting dose of sapropterin dihydrochloride powder for oral solution is 10 mg/kg taken once daily. (2.1)
• **Patients 7 years and older:** The recommended starting dose of sapropterin dihydrochloride powder for oral solution is 10 to 20 mg/kg taken once daily. (2.1)

Dosage Adjustment
• Doses of sapropterin dihydrochloride powder for oral solution may be adjusted in the range of 5 to 20 mg/kg taken once daily. (2.1)
• Monitor blood Phe regularly, especially in pediatric patients. (2.1, 5.3)
Preparation and Administration
• Take with a meal. (2.2)
• Swallow oral solution after mixing powder in a small amount of soft foods or dissolving in recommended liquids. See full prescribing information for complete information on mixing with food or liquid. (2.2)

DOSAGE FORMS AND STRENGTHS
• Powder for Oral Solution: 100 mg and 500 mg sapropterin dihydrochloride. (3)

CONTRAINDICATIONS
None. (4)

WARNINGS AND PRECAUTIONS
• **Hypersensitivity reactions including anaphylaxis:** Sapropterin dihydrochloride is not recommended in

- patients with a history of anaphylaxis to sapropterin dihydrochloride; discontinue treatment in patients who experience anaphylaxis and initiate appropriate medical treatment. Continue dietary Phe restrictions. (5.1)
- **Upper Gastrointestinal Mucosal Inflammation:** Monitor patients for signs and symptoms of these conditions including esophagitis and gastritis. (5.2)
 - **Hypophenylalaninemia:** Pediatric patients younger than 7 years treated with sapropterin dihydrochloride doses of 20 mg/kg per day are at increased risk for low levels of blood Phe compared with patients 7 years and older. (5.3)
 - **Monitoring Blood Phe Levels During Treatment:** Ensure adequate blood Phe control and nutritional balance during treatment with sapropterin dihydrochloride. Frequent blood monitoring is recommended, especially in pediatric patients. (5.4, 2.1)
 - **Lack of Biochemical Response to Sapropterin Dihydrochloride Treatment:** Response to sapropterin dihydrochloride treatment cannot be pre-determined by laboratory (e.g., molecular) testing and can only be determined by a therapeutic trial of sapropterin dihydrochloride. (5.5, 2.1)
 - **Interaction with Levodopa:** Seizures, over-stimulation or irritability may occur; monitor patients for a change in neurologic status. (5.6, 7)
 - **Hyperactivity:** Monitor patients for hyperactivity. (5.7)

ADVERSE REACTIONS
Most common adverse reactions (≥4%) are: headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Amnora Pharma Private Limited at 1-866-495-1995, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
• **Inhibitors of Folate Synthesis** (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim): Can decrease endogenous BH4 levels; monitor blood Phe levels more frequently and adjust sapropterin dihydrochloride dosage as needed. (7)
• **Drugs Affecting Nitric Oxide-Mediated Vasorelaxation** (e.g., PDE-5 inhibitors): Potential for vasorelaxation; monitor blood pressures. (7)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 09/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
3. DOSAGE FORMS AND STRENGTHS
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
6. ADVERSE REACTIONS
7. DRUG INTERACTIONS

8. USE IN SPECIFIC POPULATIONS

- 8.1. Pregnancy
- 8.2. Lactation
- 8.4. Pediatric Use
- 8.5. Geriatric Use
10. OVERDOSAGE
11. DESCRIPTION
12. CLINICAL PHARMACOLOGY
- 12.1. Mechanism of Action
- 12.2. Pharmacodynamics
- 12.3. Pharmacokinetics
13. NONCLINICAL TOXICOLOGY
- 13.1. Carcinogenesis, Mutagenesis, Impairment of Fertility
14. CLINICAL STUDIES
15. HOW SUPPLIED/STORAGE AND HANDLING
17. PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the Full Prescribing Information are not listed

FULL PRESCRIBING INFORMATION

1. INDICATIONS AND USAGE

Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet.

2. DOSAGE AND ADMINISTRATION

2.1 Dosage
Treatment with sapropterin dihydrochloride powder for oral solution should be directed by physicians knowledgeable in the management of PKU.

All patients with PKU who are being treated with sapropterin dihydrochloride powder for oral solution should also be treated with a Phe-restricted diet, including dietary protein and Phe restriction.

Starting Dosage

Pediatric Patients 1 month to 6 years: The recommended starting dose of sapropterin dihydrochloride powder for oral solution is 10 mg/kg taken once daily.

Patients 7 years and older: The recommended starting dose of sapropterin dihydrochloride powder for oral solution is 10 to 20 mg/kg taken once daily.

Dosage Adjustment (Evaluation Period)

Existing dietary protein and Phe intake should not be modified during the evaluation period.

If a 10 mg/kg per day starting dose is used, then response to therapy is determined by change in blood Phe following treatment with sapropterin dihydrochloride powder for oral solution at 10 mg/kg per day for a period of up to 1 month. Blood Phe levels should be checked after 1 week of sapropterin dihydrochloride powder for oral solution treatment and periodically for up to a month. If blood Phe does not decrease from baseline at 10 mg/kg per day, the dose may be increased to 20 mg/kg per day. Patients whose blood Phe does not decrease after 1 month of treatment at 20 mg/kg per day do not show a biochemical response and treatment with sapropterin dihydrochloride powder for oral solution should be discontinued in these patients.

If a 20 mg/kg per day starting dose is used, then response to therapy is determined by change in blood Phe following treatment with sapropterin dihydrochloride powder for oral solution at 20 mg/kg per day for a period of 1 month. Blood Phe levels should be checked after 1 week of sapropterin dihydrochloride powder for oral solution treatment and periodically during the first month. Treatment should be discontinued in patients who do not show a biochemical response (blood Phe does not decrease) after 1 month of treatment at 20 mg/kg per day (see **Warnings and Precautions** (5.4)).

Once responsiveness to sapropterin dihydrochloride powder for oral solution has been established, the dosage may be adjusted within the range of 5 to 20 mg/kg per day according to a biochemical response to therapy (blood Phe). Periodic blood Phe monitoring is recommended to assess blood Phe control, especially in pediatric patients (see **Warnings and Precautions** (5.3)).

2.2 Preparation and Administration Instructions

Take sapropterin dihydrochloride powder for oral solution orally with a meal, preferably at the same time each day (see **Clinical Pharmacology** (12.3)). A missed dose should be taken as soon as possible, but two doses should not be taken on the same day.

Sapropterin Dihydrochloride Powder for Oral Solution

Patients weighing greater than 10 kg

Sapropterin dihydrochloride powder for oral solution should be dissolved in 120 to 240 mL of water or apple juice and taken orally within 30 minutes of dissolution. Sapropterin dihydrochloride powder for oral solution may also be stirred in a small amount of apple or soft foods (e.g., apple sauce or pudding, 100 mg packets) in water, apple juice, or a small amount of soft foods and mix thoroughly. The powder should dissolve completely.

Patients weighing 10 kg or less (see 100 mg packets)

For infants weighing 10 kg or less, sapropterin dihydrochloride powder for oral solution can be dissolved in as little as 5 mL of water or apple juice and a portion of this solution corresponding to a 10 mg/kg dose may be administered orally via an oral dosing syringe. Table 1 provides dosing information for infants at the recommended starting dose of 10 mg/kg per day. Refer to Table 2 for dosing information for adults at the dosage adjustment is needed.

Table 1: 10 mg/kg per day Dosing Table for Infants Weighing 10 kg or less

Patient Weight (kg)	Starting Dose: 10 mg/kg per day			
	Dose (mg)	Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Packets Dissolved	Dilution Volume (mL) ¹	Administered Dose volume (mL) ¹
1	10	1	10	1
2	20	1	10	2
3	30	1	10	3
4	40	1	10	4
5	50	1	10	5
6	60	1	5	3
7	70	1	5	3.5
8	80	1	5	4
9	90	1	5	4.5
10	100	1	5	5

Starting doses for infants is 10 mg/kg per day. Dosing information for 20 mg/kg per day is provided in Table 2.

Powder for oral solution provided in single use packets containing 100 mg sapropterin dihydrochloride per packet

¹ Volume of water or apple juice to dissolve sapropterin dihydrochloride powder for oral solution.

² Discard remainder of mixture after volume to be administered is drawn.

Table 2: 20 mg/kg per day Dosing Table for Infants Weighing 10 kg or less

Patient Weight (kg)	20 mg/kg per day			
	Dose (mg)	Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Packets ¹ Dissolved	Dilution Volume (mL) ¹	Administered Dose volume (mL) ¹
1	20	1	5	1
2	40	1	5	2
3	60	1	5	3
4	80	1	5	4
5	100	12	5	5
6	120	2	5	3
7	140	2	5	3.5
8	160	2	5	4
9	180	2	5	4.5
10	200	2	5	5

Powder for oral solution provided in single use packets containing 100 mg sapropterin dihydrochloride per packet

¹ Volume of water or apple juice to dissolve sapropterin dihydrochloride powder for oral solution.

² Discard remainder of mixture after volume to be administered is drawn.

3. DOSAGE FORMS AND STRENGTHS

Sapropterin dihydrochloride powder for oral solution is available as a unit dose packet containing 100 mg of sapropterin dihydrochloride and as a unit dose packet containing 500 mg of sapropterin dihydrochloride. The powder is off-white to yellow in color.

4. CONTRAINDICATIONS

None.

5. WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions Including Anaphylaxis

Sapropterin dihydrochloride is not recommended in patients with a history of anaphylaxis to sapropterin dihydrochloride. Hypersensitivity reactions, including anaphylaxis and rash, have occurred (see **Adverse Reactions** (6.2)). If left untreated, these could lead to severe sequelae including esophageal stricture, esophageal ulcer, gastric ulcer, and bleeding and such complications have been reported in patients receiving sapropterin dihydrochloride. Monitor patients for signs and symptoms of upper GI mucosal inflammation.

5.3 Hypophenylalaninemia

In clinical trials of sapropterin dihydrochloride, some PKU patients experienced hypophenylalaninemia (low blood Phe) during treatment with sapropterin dihydrochloride. In a clinical study of pediatric patients younger than 7 years old treated with sapropterin dihydrochloride 20 mg/kg per day, the incidence of hypophenylalaninemia was higher than in clinical trials of older patients (see **Adverse Reactions** (6.1)).

5.4 Monitoring Blood Phe Levels During Treatment

Prolonged elevations of blood Phe levels in patients with PKU can result in severe neurologic damage, including severe intellectual disability, developmental delay, microcephaly, delayed speech, seizures, and behavioral abnormalities. Conversely, prolonged levels of blood Phe that are too low have been associated with catabolism and endogenous protein breakdown, which has been associated with adverse developmental outcomes. Active management of dietary Phe intake while taking sapropterin dihydrochloride is required to ensure adequate Phe control and nutritional balance. Monitor blood Phe levels during treatment to ensure adequate blood Phe level control. Frequent blood monitoring is recommended in the pediatric population (see **Dosage and Administration** (2.1)).

5.5 Lack of Biochemical Response to Sapropterin Dihydrochloride

Some patients with PKU do not show biochemical response (reduction in blood Phe) with treatment with sapropterin dihydrochloride. In two clinical trials at a sapropterin dihydrochloride dose of 20 mg/kg per day, 56% to 75% of pediatric PKU patients showed a biochemical response to sapropterin dihydrochloride, and in

one clinical trial at a dose of 10 mg/kg per day, 20% of adult and pediatric PKU patients showed a biochemical response to sapropterin dihydrochloride (see **Clinical Studies** (14)).

Biological response to sapropterin dihydrochloride treatment cannot generally be pre-determined by laboratory testing (e.g., molecular testing), and should be determined through a therapeutic trial (evaluation) of sapropterin dihydrochloride response (see **Dosage and Administration** (2.1)).

5.6 Interaction with Levodopa

In a 10-year post-marketing safety surveillance program for a non-PKU indication using another sapropterin product, 3 patients with underlying neurological disorders experienced seizures, exacerbation of seizures, over-stimulation, and irritability during co-administration of levodopa and sapropterin. Monitor patients who are receiving levodopa for changes in neurological status during treatment with sapropterin dihydrochloride (see **Drug Interactions** (7)).

5.7 Hyperactivity

In the sapropterin dihydrochloride post-marketing safety surveillance program, 2 patients with PKU experienced hyperactivity when treated with sapropterin dihydrochloride (see **Adverse Reactions** (6.2)). Monitor patients for hyperactivity.

6. ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

PKU Clinical Studies

The safety of sapropterin dihydrochloride was evaluated in 7 clinical studies in patients with PKU (aged 1 month to 50 years) (see **Clinical Studies** (14)).

In Studies 1 to 4 (controlled and uncontrolled studies), 578 patients with PKU aged 4 to 48 years received sapropterin dihydrochloride in doses ranging from 5 to 20 mg/kg per day for lengths of treatment ranging from 1 to 184 weeks. The patient population was evenly distributed in gender, and approximately 95% of patients were Caucasian. The most common adverse reactions (≥4% of patients) were headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion.

The data described in Table 3 reflect exposure of 74 patients with PKU to sapropterin dihydrochloride at doses of 10 to 20 mg/kg per day for 6 to 10 weeks in two double-blind, placebo-controlled clinical trials (Studies 2 and 4).

Table 3 enumerates adverse reactions occurring in at least 4% of patients treated with sapropterin dihydrochloride in the double-blind, placebo-controlled clinical trials described above.

Table 3: Summary of Adverse Reactions Occurring in ≥4% of Patients in Placebo-Controlled Clinical Studies with Sapropterin Dihydrochloride

MedDRA Preferred Term	20 mg/kg per day	
	Sapropterin Dihydrochloride (N=74)	Placebo (N=59)
	No. Patients (%)	No. Patients (%)
Headache	11 (15)	8 (14)
Rhinorrhea	8 (11)	0
Pharyngolaryngeal pain	7 (10)	1 (2)
Diarrhea	6 (8)	3 (5)
Vomiting	6 (8)	4 (7)
Cough	5 (7)	3 (5)
Nasal congestion	3 (4)	0

In open-label, uncontrolled clinical trials (Studies 1 and 3) all patients received sapropterin dihydrochloride in doses of 5 to 20 mg/kg per day, and adverse reactions were similar in type and frequency to those reported in the double-blind, placebo-controlled clinical trials (see **Clinical Studies** (14)).

In Study 5, 65 pediatric patients with PKU aged 1 month to 6 years received sapropterin dihydrochloride 20 mg/kg per day for 6 months. Adverse reactions were similar in frequency and type to those seen in other sapropterin dihydrochloride clinical trials except for an increased incidence of low Phe levels. Twenty-five percent (16 out of 65) of patients developed Phe levels below normal for age (see **Warnings and Precautions** (5.3)). **Pediatric Use** (6.4) and **Clinical Studies** (14)).

In Study 6, a long-term, open-label, extension study of 111 patients aged 4 to 50 years, receiving sapropterin dihydrochloride in doses ranging from 5 to 20 mg/kg per day, adverse reactions were similar in type and frequency to those reported in the previous clinical studies. Fifty-five patients received sapropterin dihydrochloride both as dissolved and intact tablets. There were no notable differences in the incidence or severity of adverse reactions between the two methods of administration. The mean (±SD) exposure to sapropterin for the entire study population was 658 ± 221 days (maximum 953 days).

In Study 7, 27 pediatric patients with PKU aged 0 to 4 years received sapropterin dihydrochloride 10 mg/kg per day or 20 mg/kg per day. Adverse reactions were similar in type and frequency to those observed in other clinical trials, with the addition of rhinitis, which was reported in 2 (7%) subjects (7.4%).

Safety Experience from Clinical Studies for Non-PKU Indications

Approximately 800 healthy subjects and patients with disorders other than PKU, some of whom had underlying neurologic disorders or cardiovascular diseases, have been administered a different formulation of the same active ingredient (sapropterin) at approximately 10 mg/kg per day in controlled and uncontrolled clinical trials. In these clinical trials, subjects were administered sapropterin doses ranging from 1 to 100 mg/kg per day for lengths of exposure from 1 day to 2 years. Serious and severe adverse reactions (regardless of causality) during sapropterin administration were seizures, exacerbation of seizures (see **Warnings and Precautions** (5.3)), dizziness, gastrointestinal bleeding, post-procedural bleeding, headache, irritability, myocardial infarction, overstimulation, and respiratory failure. Common adverse reactions were headache, peripheral edema, arthralgia, polyuria, agitation, dizziness, nausea, pharyngitis, abdominal pain, upper abdominal pain, and upper respiratory tract infection.

6.2 Postmarketing Experience

The following adverse reactions have been reported during post-approval use of sapropterin dihydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity reactions including anaphylaxis and rash: Most hypersensitivity reactions occurred within several days of initiating treatment (see **Warnings and Precautions** (5.1)).

Gastrointestinal reactions: esophagitis, gastritis, oropharyngeal pain, pharyngitis, esophageal pain, abdominal pain, dyspepsia, nausea, and vomiting (see **Warnings and Precautions** (5.2)).

Hyperactivity: Two cases have been reported. In one case, the patient received an accidental overdose of sapropterin dihydrochloride (see **Warnings and Precautions** (5.6)). **Overdosage** (10)).

7. DRUG INTERACTIONS

Table 4 includes drugs with clinically important drug interactions when administered with sapropterin dihydrochloride and instructions for preventing or managing them.

Table 4: Clinically Relevant Drug Interactions

Levodopa	Clinical Impact: Sapropterin dihydrochloride may increase the availability of tyrosine, a precursor of levodopa. Neurologic events were reported post-marketing in patients receiving sapropterin and levodopa concomitantly for a non-PKU indication (see Warnings and Precautions (5.5)).
Inhibitors of Folate Synthesis (e.g., methotrexate, valproic acid, phenobarbital, trimethoprim)	Intervention: Monitor patients for a change in neurologic status.
Clinical Impact: <i>In vitro</i> and <i>in vivo</i> nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. This reduction in net BH4 levels may increase Phe levels.	Intervention: Consider monitoring blood Phe levels more frequently during concomitant administration. An increased dosage of sapropterin dihydrochloride may be necessary to achieve a biochemical response.
Drugs Affecting Nitric Oxide-Mediated Vasorelaxation (e.g., PDE-5 inhibitors such as sildenafil, vardenafil, or tadalafil)	Clinical Impact: Both sapropterin dihydrochloride and PDE-5 inhibitors may induce vasorelaxation. A reduction in blood pressure could occur; however, the combined use of these medications has not been evaluated in humans.
Intervention: Monitor blood pressure.	

8. USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary


Available pregnancy registry data have not reported an association with sapropterin dihydrochloride and major birth defects, miscarriage, or adverse maternal or fetal outcomes when sapropterin dihydrochloride was used during pregnancy (see **Data**).

An embryo-fetal development study with sapropterin dihydrochloride in rats using oral doses up to 3 times the maximum recommended human dose (MRHD) given during the period of organogenesis showed no effects. In a rabbit study using oral administration of sapropterin dihydrochloride during the period of organogenesis, x-ray detect, holoprosencephaly, was noted at 10 times the MRHD. All pregnancies have a background risk of major birth defects, pregnancy loss, or other adverse pregnancy outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated background risk of major birth defects and miscarriage in pregnant women with PKU who maintain blood phenylalanine concentrations greater than 600 micromol/L during pregnancy is greater than the corresponding background risk for pregnant women without PKU.

Clinical Considerations

Disease-Associated Maternal and/or Embryo-Fetal Risk

Uncontrolled blood phenylalanine concentrations before and during pregnancy are associated with an increased risk of adverse pregnancy outcomes and fetal adverse effects. To reduce the risk of hyperphenylalaninemia-induced fetal adverse effects, blood phenylalanine concentrations should be maintained between 120 and 360 micromol/L during pregnancy and during the 3 months before conception (see **Dosage and Administration** (2.1)).



Sapropterin Dihydrochloride

2102106

PATIENT INFORMATION
Sapropterin Dihydrochloride Powder for Oral Solution
(sap-roe-TER-in-dye-HYE-droe-KLOR-ide)

What is sapropterin dihydrochloride powder for oral solution?

Sapropterin dihydrochloride powder for oral solution is a prescription medicine used to lower blood levels of phenylalanine (Phe), in adults and children one month of age and older with a certain type of Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is used along with a Phe-restricted diet.

What should I tell my doctor before taking sapropterin dihydrochloride powder for oral solution?

Before you take sapropterin dihydrochloride powder for oral solution, tell your doctor about all your medical conditions, including if you:

- are allergic to sapropterin dihydrochloride or any of the ingredients in sapropterin dihydrochloride powder for oral solution. See the list of ingredients in sapropterin dihydrochloride powder for oral solution at the end of this leaflet.
- have poor nutrition or have loss of appetite.
- are pregnant or plan to become pregnant.
- are breastfeeding or plan to breastfeed. It is not known if sapropterin dihydrochloride passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take sapropterin dihydrochloride powder for oral solution.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal, and dietary supplements. Sapropterin dihydrochloride powder for oral solution and other medicines may interact with each other.

Especially tell your doctor if you take:

- a medicine that contains levodopa
- an antifolate medicine
- sildenafil (Revatio, Viagra), tadalafil (Aldicra, Cialis), vardenafil (Staxyn, Levitra)

Tell your doctor if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I take sapropterin dihydrochloride powder for oral solution?

- Take sapropterin dihydrochloride powder for oral solution exactly as your doctor tells you. Your doctor should tell you how much sapropterin dihydrochloride powder for oral solution to take and when to take it.
- Your doctor may change your dose of sapropterin dihydrochloride powder for oral solution depending on how you respond to treatment.
- Take sapropterin dihydrochloride powder for oral solution 1 time each day with a meal. It is best to take sapropterin dihydrochloride powder for oral solution at the same time each day.
- Sapropterin dihydrochloride comes as powder for oral solution.
 - Be sure that you know what dose of sapropterin dihydrochloride powder your doctor prescribed and whether you should use sapropterin dihydrochloride 100 mg packets, sapropterin dihydrochloride 500 mg packets, or both types of packets to prepare your dose.
 - Open sapropterin dihydrochloride powder packets only when you are ready to use them.
 - Sapropterin dihydrochloride powder for oral solution should be dissolved in water or apple juice. You may also mix the powder for oral solution in a small amount of soft food, such as apple sauce or pudding before taking.
 - See the detailed “Instructions for Use” that comes with sapropterin dihydrochloride powder for oral solution for information about the correct way to dissolve and take a dose of sapropterin dihydrochloride powder for oral solution.

It is not possible to know if sapropterin dihydrochloride powder for oral solution will work for you until you start taking sapropterin dihydrochloride powder for oral solution. Your doctor will check your blood Phe levels when you start taking sapropterin di

Instructions for Use

Saproterin Dihydrochloride Powder for Oral Solution

(SAP-roe-TER-in dye-HYE-droe-KLOR-ide)

Read this Instructions for Use before you start taking saproterin dihydrochloride powder for oral solution and each time you refill your prescription. There may be new information. This information does not take the place of talking with your healthcare provider about your treatment. Talk to your doctor if you have any questions about the right dose of saproterin dihydrochloride powder for oral solution to take or how to mix it.

Important information:

- Saproterin dihydrochloride powder for oral solution comes in a packet containing powder.
- Take saproterin dihydrochloride powder for oral solution exactly as your doctor tells you. Your doctor should tell you how much saproterin dihydrochloride powder for oral solution to take and when to take it.
- Your doctor may change your dose of saproterin dihydrochloride powder for oral solution depending on how you respond to treatment, or based on your baby's weight.
- If your baby weighs 22 pounds or less, follow the section called "Instructions for giving saproterin dihydrochloride powder for oral solution (saproterin dihydrochloride 100 mg packets) to babies who weigh 22 pounds or less".
- Take saproterin dihydrochloride powder for oral solution 1 time each day with a meal. It is best to take saproterin dihydrochloride powder for oral solution at the same time each day.

Instructions for taking saproterin dihydrochloride powder for oral solution:

For babies who weigh 22 pounds or less, see the section below called "Instructions for giving saproterin dihydrochloride powder for oral solution (saproterin dihydrochloride 100 mg packets) to babies who weigh 22 pounds or less."

Saproterin dihydrochloride powder for oral solution should be dissolved in water or apple juice. The powder for oral solution may also be mixed in a small amount of soft foods, such as apple sauce or pudding.

To dissolve saproterin dihydrochloride powder for oral solution:

- Be sure that you know what dose of saproterin dihydrochloride powder for oral solution your doctor has prescribed and whether you should use saproterin dihydrochloride 100 mg packets, saproterin dihydrochloride 500 mg packets, or both types of packets to prepare your dose.
- Open the packet(s) of saproterin dihydrochloride powder for oral solution by folding and tearing, or cutting at the dotted line in the upper right corner of the packet. Open the packet(s) only when you are ready to use them.
- Empty the contents of the packet(s) into 4 ounces to 8 ounces (1/2 cup to 1 cup) of water or apple juice.
- Drink within 30 minutes.

Instructions for giving saproterin dihydrochloride powder for oral solution (saproterin dihydrochloride 100 mg packets) to babies who weigh 22 pounds or less:

- The dose of saproterin dihydrochloride powder for oral solution is based on body weight. This will change as your baby grows. Your doctor will tell you:
 - the number of saproterin dihydrochloride 100 mg packets needed for one dose
 - the amount of water or apple juice needed to mix one dose of saproterin dihydrochloride powder for oral solution
 - the amount of the mixture (powder and water or apple juice) you will need to give your baby his or her prescribed dose of medicine.
- Give your baby the prescribed amount of mixture (powder and water or apple juice) within 30 minutes after mixing. If you are not able to give your baby's dose within 30 minutes after mixing, pour the unused medicine into the trash. You will need to mix a new dose.

Supplies needed to mix and give your baby's dose of saproterin dihydrochloride powder for oral solution:

- the number of saproterin dihydrochloride 100 mg packets needed for one dose
- a small cup of water or apple juice
- one 30 mL medicine cup for mixing
- small spoon or clean utensil for mixing
- 10 mL oral dosing syringe
- scissors (optional)

Ask your pharmacist for a 30 mL medicine cup for mixing and an oral dosing syringe if you do not have these supplies.

Step 1: Find a clean, flat work surface.

Step 2: Place a small cup of water or apple juice, the oral dosing syringe, and an empty medicine cup on your clean, flat work surface (see Figure A).

Step 3: Pour 5 mL or 10 mL of water or apple juice from the small cup into the medicine cup, as instructed by your doctor. Check to make sure that the amount of liquid lines up with the amount that your doctor tells you (see Figure B).

Step 4: Check the label on the saproterin dihydrochloride powder for oral solution packet(s). If the packet is marked saproterin dihydrochloride powder for oral solution 100 mg, empty the entire contents of the saproterin dihydrochloride powder for oral solution packet into the medicine cup (see Figure C).

Step 5: Stir the mixture with the small spoon or other clean utensil until all of the powder completely dissolves (see Figure D).

Step 6: To give a dose of saproterin dihydrochloride powder for oral solution to your baby: Place the tip of the oral dosing syringe into the liquid inside the medicine cup. Pull back on the plunger and draw up the amount of the mixture prescribed by your doctor (see Figure E).

Step 7: Take the oral dosing syringe out of the medicine cup. Carefully turn the oral dosing syringe so that the tip is pointing up. Check to make sure that the amount of medicine in the oral dosing syringe lines up with the amount of mixture prescribed by your doctor (see Figure F).

Step 8: Place the tip of the oral dosing syringe into your baby's mouth. Point the tip of the oral dosing syringe toward either cheek (see Figure G).

Push on the plunger slowly, a small amount at a time, until all of the mixture in the oral dosing syringe is given.

Step 9: Throw away any remaining mixture. Remove the plunger from the barrel of the oral dosing syringe. Wash the oral dosing syringe and medicine cup with warm water and air dry. When the oral dosing syringe is dry, put the plunger back into the barrel. Store the oral dosing syringe and medicine cup for the next use.

How should I store saproterin dihydrochloride powder for oral solution?

- Store saproterin dihydrochloride powder for oral solution at room temperature between 68°F to 77°F (20°C to 25°C).
- Protect from moisture.

Keep saproterin dihydrochloride powder for oral solution and all medicines out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

The brands listed are the registered trademarks of their respective owners and are not trademarks of Annora Pharma Private Limited.



Manufactured for:
Camber Pharmaceuticals, Inc.
Piscataway, NJ 08854

By: Annora Pharma Pvt. Ltd.
Sangareddy - 502313, Telangana, India.

Revised: 09/2022

Data

Human Data

Uncontrolled Maternal PKU

Available data from the Maternal Phenylketonuria Collaborative Study on 468 pregnancies and 331 live births in PKU-affected women demonstrated that uncontrolled Phe levels above 600 micromol/L are associated with a very high incidence of neurological, cardiac, facial dysmorphism, and growth anomalies. Control of blood phenylalanine during pregnancy is essential to reduce the incidence of Phe-induced teratogenic effects.

Animal Data

No effects on embryo-fetal development were observed in a reproduction study in rats using oral doses of up to 400 mg/kg per day saproterin dihydrochloride (about 3 times the MMRD of 20 mg/kg per day, based on body surface area) administered during the period of organogenesis. However, in a rabbit reproduction study, oral administration of a maximum dose of 800 mg/kg per day (about 10 times the MMRD, based on body surface area) during the period of organogenesis was associated with a non-statistically significant increase in the incidence of holoprosencephaly in two high-dose-treated litters (4 fetuses), compared to one control-treated litter (1 fetus).

8.2 Lactation

Risk Summary

There are insufficient data to assess the presence of saproterin in human milk and no data on the effects on milk production. In postmarketing pregnancy registries, a total of 16 women from both registries were identified as breastfeeding for a mean of 3.5 months. No lactation-related safety concerns were reported in infants of mothers nursing during maternal treatment with saproterin dihydrochloride. Saproterin is present in the milk of lactating rats following intravenous administration, but not following oral administration.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for saproterin dihydrochloride and any potential adverse effects on the breastfed child from saproterin dihydrochloride or from the underlying maternal condition.

8.4 Pediatric Use


Pediatric patients with PKU, ages 1 month to 16 years, have been treated with saproterin dihydrochloride in clinical trials (see Clinical Studies (14)).

The efficacy and safety of saproterin dihydrochloride have not been established in neonates. The safety of saproterin dihydrochloride has been established in children younger than 4 years in trials of 6 months duration and in children 4 years and older in trials of up to 3 years in length (see Adverse Reactions (6.1)).

In children aged 1 month and older, the efficacy of saproterin dihydrochloride has been demonstrated in trials of 6 weeks or less in duration (see Clinical Studies (14)).

In a multicenter, open-label, single-arm study, 57 patients aged 1 month to 6 years who were defined as saproterin dihydrochloride responders after 4 weeks of saproterin dihydrochloride treatment and Phe dietary restriction were treated for 6 months with saproterin dihydrochloride at 20 mg/kg per day. The effectiveness of saproterin dihydrochloride alone on reduction of blood Phe levels beyond 4 weeks could not be determined due to concurrent changes in dietary Phe intake during the study. Mean (±SD) blood Phe values over time for patients aged 1 month to < 2 years and 2 to < 7 years are shown in Figure 1.

Figure 1: Mean Blood Phe Level Over Time by Age (years) (N=57)



8.5 Geriatric Use

Clinical studies of saproterin dihydrochloride in patients with PKU did not include patients aged 65 years and older. It is not known whether these patients respond differently than younger patients.

10 OVERDOSAGE

Two unintentional overdoses with saproterin dihydrochloride have been reported. One adult patient in a saproterin dihydrochloride clinical trial received a single saproterin dihydrochloride dose of 4,500 mg (36 mg/kg) instead of 2,600 mg (20 mg/kg). The patient reported mild headache and mild dizziness immediately after taking the dose; both symptoms resolved within 1 hour with no treatment intervention. There were no associated laboratory test abnormalities. The patient suspended therapy for 24 hours and then restarted saproterin dihydrochloride with no reports of abnormal signs or symptoms. In postmarketing, one pediatric patient received saproterin dihydrochloride doses of 45 mg/kg per day instead of 20 mg/kg per day. The patient reported hyperactivity that began at an unspecified time after overdosage and resolved after the saproterin dihydrochloride dose was reduced to 20 mg/kg per day.


In a clinical study to evaluate the effects of saproterin dihydrochloride on cardiac repolarization, a single supra-therapeutic dose of 100 mg/kg (5 times the maximum recommended dose) was administered to 54 healthy adults. No serious adverse reactions were reported during the study. The only adverse reactions reported were in 1 subject who received the supra-therapeutic dose were upper abdominal pain (8%) and dizziness (4%). A dose-dependent shortening of the QT interval was observed (see Clinical Pharmacology (12.2)).

Patients should be advised to notify their physicians in cases of overdosage.

11 DESCRIPTION

Saproterin dihydrochloride is an orally administered Phenylalanine Hydroxylase activator (or PAH activator). Saproterin dihydrochloride, the active pharmaceutical ingredient in saproterin dihydrochloride powder for oral solution, is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Saproterin dihydrochloride is a white to pale yellow color powder.

The chemical name of saproterin dihydrochloride is (6R)-2-amino-6-[(1R,2S)-1,2-dihydroxypropyl]-5,6,7,8-tetrahydro-4(1H)-pteridine dinucleoside and the molecular formula is C₁₄H₁₆N₄O₂·2HCl with a molecular weight of 314.17. Saproterin dihydrochloride has the following structural formula:



Saproterin dihydrochloride is supplied as powder for oral solution containing 100 mg of saproterin dihydrochloride (equivalent to 76.8 mg of saproterin base). Saproterin dihydrochloride is also supplied as powder for oral solution containing 500 mg of saproterin dihydrochloride (equivalent to 384 mg of saproterin base).

Saproterin dihydrochloride powder for oral solution is off-white to yellow in color. Each unit dose packet contains the following inactive ingredients: ascorbic acid, mannitol, potassium citrate monohydrate and sucralose.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Saproterin dihydrochloride is a synthetic form of BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients.

12.2 Pharmacodynamics

In PKU patients who are responsive to BH4 treatment, blood Phe levels decrease within 24 hours after a single administration of saproterin dihydrochloride, although maximal effect on the level may take up to a month, depending on the patient. A single daily dose of saproterin dihydrochloride is adequate to maintain stable blood Phe levels over a 24-hour period. Twelve patients with blood Phe levels ranging from 516 to 986 µmol/L (mean 747 ± 153 µmol/L) were assessed with 24-hour blood Phe level monitoring following a daily morning dose of 10 mg/kg per day. The blood Phe level remained stable during a 24-hour observation period. No substantial increases in blood Phe levels were observed following food intake throughout the 24-hour period.

Saproterin dihydrochloride dose-response relationship was studied in an open-label, forced titration study at doses of 5 mg/kg per day, then 20 mg/kg per day, and then 100 mg/kg per day (31) (see Clinical Studies (14.1)). Individual blood Phe levels were highly variable among patients. The mean blood Phe level observed at the end of each 2-week dosing period decreased as the dose of saproterin dihydrochloride increased, demonstrating an inverse relationship between the dose of saproterin dihydrochloride and mean blood Phe levels.

Cardiac Electrophysiology

A thorough QTc study was performed in 56 healthy adults. This randomized, placebo and active controlled crossover study was conducted to determine if a single supra-therapeutic (100 mg/kg) dose of saproterin dihydrochloride or a single therapeutic dose (20 mg/kg) of saproterin dihydrochloride had an effect on cardiac repolarization. In this study, saproterin dihydrochloride was administered after discarding tablets in water under fed condition. This study demonstrated a dose-dependent shortening of the QT interval. The maximum placebo-subtracted mean change from baseline of the QTc interval was -3.68 and -8.32 ms (lower bound of 90% CI: -5.3 and -10.6 ms) at 20 and 100 mg/kg, respectively.

12.3 Pharmacokinetics

Studies in healthy subjects have shown comparable absorption of saproterin when tablets are dissolved in water or orange juice and taken under fasted conditions. Administration of dissolved tablets after a high-fat/high-calorie meal resulted in mean increases in C_{max} of 84% and AUC of 87% (dissolved in water). However, there was extensive variability in individual subject values for C_{max} and AUC across the different modes of administration and meal conditions. In the clinical trials of saproterin dihydrochloride, drug was administered in the morning as a dissolved tablet without regard to meals. The mean elimination half-life in PKU patients was approximately 6.7 hours (range 3.9 to 17 hours), comparable with values seen in healthy subjects (range 3.0 to 5.3 hours).

A study in healthy adults with 10 mg/kg of saproterin dihydrochloride demonstrated that the absorption via intact tablet administration was 40% greater than via dissolved tablet administration under fasted conditions based on AUC_{0-∞}. The administration of intact tablets under fed conditions resulted in an approximately 43% increase in the extent of absorption compared to fasted conditions based on AUC_{0-∞} (see Pharmacokinetics (12.2)).

Population pharmacokinetic analysis of saproterin including patients from 1 month to 49 years of age showed that body weight is the only covariate substantially affecting clearance or distribution volume (see Table 5). Pharmacokinetics in patients > 49 years of age have not been studied.

Table 5. Apparent Plasma Clearance by Age

Parameter	0 to < 1 yr (N=10)	1 to < 6 yr (N=57)	6 to < 12 yr (N=23)	12 to < 18 yr (N=24)	≥ 18 yr (N=42)
CL/F (L/h/kg) Mean ± SD (Median)	81.5 ± 92.4 (53.6)	50.7 ± 20.1 (48.4)	51.7 ± 21.9 (47.4)	38.2 ± 9.3 (38.3)	37.9 ± 20.2 (31.8)

* Evaluated at 20 mg/kg per day doses
Evaluated at 5, 10, or 20 mg/kg per day doses

Metabolism

Saproterin is a synthetic form of tetrahydrobiopterin (BH4) and is expected to be metabolized and recycled by the same endogenous enzymes. *In vivo* endogenous BH4 is converted to quinoid dihydrobiopterin and is metabolized to dihydrobiopterin and biopterin. The enzymes dihydrofolate reductase and dihydropteridine reductase are responsible for the metabolism and recycling of BH4.

Drug Interaction Studies

Clinical Studies

In healthy subjects, administration of a single dose of saproterin dihydrochloride at the maximum therapeutic dose of 20 mg/kg had no effect on the pharmacokinetics of a single dose of digoxin (P-gp substrate) administered concomitantly.

In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically

The potential for saproterin to induce or inhibit cytochrome P450 enzymes was evaluated in *in vitro* studies which showed saproterin did not inhibit CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4/5, nor induce CYP 1A2, 2B6, or 3A4/5.

In vitro saproterin did not inhibit OAT1, OAT3, OCT2, MATE1, and MATE2-K transporters. The potential for saproterin to inhibit OATP1B1 and OATP1B3 has not been adequately studied. *In vitro*, saproterin inhibits breast cancer resistance (BCRP) but the potential for a clinically significant increase in systemic exposure of BCRP substrates by saproterin dihydrochloride appears to be low.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

A 2-year carcinogenicity study was conducted in F344 rats, and a 78-week carcinogenicity study was conducted in CD-1 mice. In the 104-week oral carcinogenicity study in rats, saproterin dihydrochloride doses of 25, 80, and 250 mg/kg per day (0.2, 0.7, and 2 times the maximum recommended human dose of 20 mg/kg per day, respectively, based on body surface area) were used. In the 78-week oral carcinogenicity study in mice, saproterin dihydrochloride doses of 25, 80, and 250 mg/kg per day (0.1, 0.3, and 2 times the maximum recommended human dose, respectively, based on body surface area) were used. In the 2-year rat carcinogenicity study, there was a statistically significant increase in the incidence of benign adrenal pheochromocytoma in male rats treated with the 250 mg/kg per day (about 2 times the maximum recommended human dose, based on body surface area) dose, as compared to vehicle treated rats. The mouse carcinogenicity study showed no evidence of a carcinogenic effect, but the study was not ideal due to its duration of 78 instead of 104 weeks.

Saproterin dihydrochloride was genotoxic in the *in vitro* Ames test at concentrations of 625 mcg (TA98) and 5000 mcg (TA100) per plate, without metabolic activation. However, no genotoxicity was observed in the *in vitro* Ames test with metabolic activation. Saproterin dihydrochloride was genotoxic in the *in vitro* chromosomal aberration assay in Chinese hamster lung cells at concentrations of 0.25 and 0.5 mM. Saproterin dihydrochloride was not mutagenic in the *in vivo* micronucleus assay in mice at doses up to 2000 mg/kg per day (about 8 times the maximum recommended human dose of 20 mg/kg per day, based on body surface area). Saproterin dihydrochloride, at oral doses up to 400 mg/kg per day (about 3 times the maximum recommended human dose, based on body surface area) was found to have no effect on fertility and reproductive function of male and female rats.

14 CLINICAL STUDIES

The efficacy of saproterin dihydrochloride was evaluated in five clinical studies in patients with PKU.

Study 1 was a multicenter, open-label, uncontrolled clinical trial of 489 patients with PKU, ages 8 to 48 years (mean 22 years), who had baseline blood Phe levels ≥ 450 µmol/L and who were not on Phe-

restricted diets. All patients received treatment with saproterin dihydrochloride 10 mg/kg per day for 6 days. For the purposes of this study, response to saproterin dihydrochloride treatment was defined as a ≥ 30% decrease in blood Phe from baseline. At Day 6, 56 patients (20%) were identified as responders.

Study 2 was a multicenter, double-blind, placebo-controlled study of 88 patients with PKU who responded to saproterin dihydrochloride in Study 1. After a washout period from Study 1, patients were randomized equally to either saproterin dihydrochloride 10 mg/kg per day (N=41) or placebo (N=47) for 6 weeks. Efficacy was assessed by the mean change in blood Phe level from baseline to Week 6 in the saproterin dihydrochloride-treated group as compared to the mean change in the placebo group.

The results showed that at baseline, the mean (±SD) blood Phe level was 843 (±300) µmol/L in the saproterin dihydrochloride-treated group and 888 (±323) µmol/L in the placebo group. At Week 6, the saproterin dihydrochloride-treated group had a mean (±SD) blood Phe level of 607 (±377) µmol/L, and the placebo group had a mean blood Phe level of 891 (±348) µmol/L. At Week 6, the saproterin dihydrochloride- and placebo-treated groups had mean changes in blood Phe level of -239 and 5 µmol/L, respectively (mean percent changes of -29% (±32) and 3% (±33), respectively). The difference between the groups was statistically significant (p < 0.001) (Table 6).

Table 6: Blood Phe Results in Study 2


	Saproterin (N=41)	Placebo (N=47)
Baseline Blood Phe Level (µmol/L)		
Mean (±SD)	843 (±300)	888 (±323)
Percentiles (25 th , 75 th)	620, 990	618, 1141
Week 6 Blood Phe Level (µmol/L)		
Mean (±SD)	607 (±377)	891 (±348)
Percentiles (25 th , 75 th)	307, 812	619, 1143
Mean Change in Blood Phe From Baseline to Week 6 (µmol/L)		
Adjusted Mean (±SE) ¹	-239 (±38)	6 (±36)
Percentiles (25 th , 75 th)	-397, -92	-96, 93
Mean Percent Change in Blood Phe From Baseline to Week 6		
Mean (±SD)	-29 (±32)	3 (±33)
Percentiles (25 th , 75 th)	-61, -11	-13, 12

¹The mean baseline levels shown in this table represent the mean of 3 pretreatment levels (Wk -2, Wk -1, and Wk 0). Treatment with saproterin dihydrochloride or placebo started at Wk 0.

²p-value < 0.001, adjusted mean and standard error from an ANCOVA model with change in blood Phe level from baseline to Week 6 as the response variable, and both treatment group and baseline blood Phe level as covariates.

Change in blood Phe was noted in the saproterin dihydrochloride-treated group at Week 1 and was sustained through Week 6 (Figure 2).

Figure 2: Mean Blood Phenylalanine (Phe) Level Over Time*



*Error bars indicate 95% confidence interval.

Study 3 was a multicenter, open-label, extension study in which 80 patients who responded to saproterin dihydrochloride treatment in Study 1 and completed Study 2 underwent 6 weeks of forced dose-titration with 3 different doses of saproterin dihydrochloride. Treatments consisted of 3 consecutive 2-week courses of saproterin dihydrochloride at doses of 5, then 20, and then 100 mg/kg per day. Blood Phe level was monitored after 2 weeks of treatment at each dose level. At baseline, mean (±SD) blood Phe was 844 (±388) µmol/L. At the end of treatment with 5, 10, and 20 mg/kg per day, mean (±SD) blood Phe levels were 744 (±384) µmol/L, 640 (±382) µmol/L, and 581 (±399) µmol/L, respectively (Table 7).

Table 7: Blood Phe Results From Forced Dose-Titration in Study 3

Saproterin Dihydrochloride Dose Level (mg/kg per day)	No. of Patients	Mean (±SD) Blood Phe Level (µmol/L)	Mean Changes (±SD) in Blood Phe Level From Week 0 (µmol/L)
Baseline (No Treatment)	80	844 (±388)	-
5	80	744 (±384)	100 (±295)
10	80	640 (±382)	-204 (±303)
20	80	581 (±399)	-263 (±318)

Study 4 was a multicenter study of 90 pediatric patients with PKU, ages 4 to 12 years, who were on Phe-restricted diets and who had blood Phe levels ≤ 480 µmol/L at screening. All patients were treated with open-label saproterin dihydrochloride 20 mg/kg per day for 8 days. Response to saproterin dihydrochloride was defined as a ≥ 30% decrease in blood Phe from baseline at Day 8. At Day 8, 50 patients (56%) had a ≥ 30% decrease in blood Phe.

Study 5 was an open label, single arm, multicenter trial in 93 pediatric patients with PKU, aged 1 month to 6 years, who had Phe levels greater than or equal to 360 µmol/L at screening. All patients were treated with saproterin dihydrochloride at 20 mg/kg per day and maintained on a Phe-restricted diet. At Week 4, 57 patients (61%) were identified as responders (defined as ≥ 30% decrease in blood Phe from baseline) (see Figure 1 section 8.4).

16 HOW SUPPLIED/STORAGE AND HANDLING

Saproterin Dihydrochloride Powder for Oral Solution

Supplied as off-white to yellow powder supplied in unit dose packets as follows:

100 mg saproterin dihydrochloride per packet:
Carton of 30 unit dose packets NDC 31722-047-30
Single unit dose packet NDC 31722-047-01
Carton of 1 unit dose packet NDC 31722-047-31

500 mg saproterin dihydrochloride per packet:
Carton of 30 unit dose packets NDC 31722-048-30
Single unit dose packet NDC 31722-048-01
Carton of 1 unit dose packet NDC 31722-048-31

Storage

Store saproterin dihydrochloride powder for oral solution at 20°C to 25°C (68°F to 77°F); excursions allowed between 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature). Protect from moisture.

17 PATIENT COUNSELING INFORMATION

Advise the patient or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Hypersensitivity Reactions Including Anaphylaxis

Advise patients and caregivers to discontinue saproterin dihydrochloride powder for oral solution and contact the patient's healthcare provider immediately if they experience symptoms of anaphylaxis, including (but not limited to) wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Continue nutritional management including dietary protein and Phe restriction (see Warnings and Precautions (5.1)).

Upper Gastrointestinal Mucosal Irritation

Advise patients and caregivers to contact their healthcare provider if the patient experiences signs and symptoms suggestive of upper GI mucosal irritation, including nausea, vomiting, dysphagia, dyspepsia, loss of appetite, oropharyngeal/esophageal, or upper abdominal pain (see Warnings and Precautions (5.3)).

Hypophenylalaninemia (low blood Phe levels), especially in pediatric patients, may cause hypophenylalaninemia (low blood Phe levels), especially in pediatric patients, may cause

Monitoring of Blood Phe Levels (see Warnings and Precautions (5.4))